IPA

Daueraufträge (SDI) sind für Premium-Kunden möglich.

IPA Section Headings (SH) IPA-Klassifikationssystem) (siehe Anhang)

CAS- Numbers (CR) (Chemical Abstracts Service Registry Numbers)

Controlled Terms (CT) (kontrollierte Deskriptoren, zum Teil aus dem MeSH)

Uncontrolled Terms (UT) (unkontrollierte bzw. semikontrollierte Deskriptoren zur Ergänzung des Titels)

Sprache des Vokabulars: Englisch

Mögliche Auswahl der Datenbank in der DIMDI ClassicSearch: SBAS IA70

Thema: Arbeiten zur Galenik des Ticlopidin

Wegen der häufig schwer überschaubaren Nomenklatur chemischer Verbindungen sollten Sie stets zusätzliche Synonyme und gegebenenfalls weitere CAS-Nummern der chemischen Verbindung ermitteln.

Suchprofil:

Thema: Wirkung von Carbamazepin bei Patienten im Kindesalter

Suchprofil:

DIMDI: IPA (IA70) © Thomson Reuters

ND:	IP0800074
AU:	Kang HC; Eun BL; Lee CW; Kim HD; Korean Pediatric Topiramate Study; et al
TI:	The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy
SO:	Epilepsia; VOL: 48 (9); p. 1716-1723 /2007/
LA:	English
ISSN:	0013-9580
CS:	Yonsei Univ, Coll Med, 134 Shinchon Dong, Seoul 120752, South Korea
RN:	0030
SC:	04 ... Toxicity; 06 ... Drug Evaluations
SH:	Toxicity; Drug Evaluations
CT:	Topiramate; Carbamazepine; Anticonvulsants; Drug comparisons; Toxicity; Cognition disorders; Behavioral and mental disorders; Dosage; Pediatrics; HUMAN
UT:	carbamazepine and topiramate; topiramate and carbamazepine
TE:	Topiramate/97240-79-4; Carbamazepine/298-46-4
CR:	97240-79-4; 298-46-4
GRC:	Anticonvulsants/28.12
AB:	Methods: A multicenter, randomized, open-label, observer-blinded, parallel-group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment. Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM. Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups
Volltext
*** End of SHOW ***

Ausgabe-Format: SHOW F=ALL

1. Liste der PreProcessed Searches

Für die folgenden Themen sind vorprozessierte Suchabfragen vorhanden:

ADVERSE DRUG REACTIONS
AIDS
ANIMAL
CANCER
ECOTOXICITY
HEAVY METALS
HUMAN
MUTAGENICITY
OCCUPATIONAL  EXPOSURE
PHARMACOKINETICS
POISONING
SENSITIZATION
TERATOGENICITY
TOXICOLOGY

2. Liste der Subject Headings (SH)

ADVERSE DRUG REACTIONS
BIOPHARMACEUTICSDRUG ANALYSIS
DRUG EVALUATIONS
DRUG INTERACTIONS
DRUG METABOLISM AND BODY DISTRIBUTION
DRUG STABILITY
ENVIRONMENTAL TOXICITY
HISTORY
INFORMATION PROCESSING AND LITERATURE
INSTITUTIONAL PHARMACY PRACTICE
INVESTIGATIONAL DRUGS
LEGISLATION, LAWS AND REGULATIONS
METHODOLOGY
MICROBIOLOGY
PHARMACEUTICAL CHEMISTRY
PHARMACEUTICAL EDUCATION
PHARMACEUTICAL TECHNOLOGY
PHARMACEUTICS
PHARMACOGNOSY
PHARMACOLOGY
PHARMACY PRACTICE
PRELIMINARY DRUG TESTING
SOCIOLOGY, ECONOMICS AND ETHICS
TOXICITY